预约演示
更新于：2026-08-26
Lidocaine/Prilocaine
复方利多卡因
更新于：2026-08-26
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1992-12-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H42N4O2 |
InChIKeyWZSPWMATVLBWRS-UHFFFAOYSA-N |
CAS号101362-25-8 |
关联
302
项与 复方利多卡因 相关的临床试验CTRI/2025/09/095420
Optimizing Palatal Anesthesia in Children: EMLA Cream with Different Drug Delivery Systems
NCT07778043
Lidocaine-prilocaine Cream as Analgesia for In-office Levator Muscle Trigger Point Injections: a Pilot Randomized, Double-blinded, Placebo-controlled Trial
NCT07768059
A Double-blind Placebo-controlled Randomized Controlled Trial (RCT) of Self-application of Lidocaine 2.5%/Prilocaine 2.5% Cream for Intrauterine Device (IUD) Insertion and Endometrial Biopsy
100 项与 复方利多卡因 相关的临床结果
登录后查看更多信息
100 项与 复方利多卡因 相关的转化医学
登录后查看更多信息
100 项与 复方利多卡因 相关的专利（医药）
登录后查看更多信息
999
项与 复方利多卡因 相关的文献（医药）2026-07-01Minerva Anestesiologica
Chronic pain after mastectomy: current knowledge and knowledge gaps
Review
作者: Khan, Savera ; Payne, Cathryn ; Palmquist, Emily ; Curatolo, Michele ; Chiu, Abby P
Post-mastectomy pain syndrome (PMPS) is a frequent and burdensome complication of breast cancer surgery, manifesting as persistent pain following mastectomy, typically with neuropathic characteristics. This review synthesizes current knowledge on the epidemiology, prevention, and treatment of PMPS, and highlight knowledge gaps to inform future research. PMPS occurs in 28-52% of patients. It is associated with impairment in quality of life, and reductions in physical and psychosocial functioning. Consistently identified risk factors include younger age, extensive axillary surgery, total mastectomy, and preexisting chronic pain. Perioperative preventive strategies, such as topical EMLA cream, pregabalin, PECS II block, i.v. dexmedetomidine and flurbiprofen axetil, show potentially promising effects in reducing the incidence or severity of PMPS. Treatment options for established PMPS with potentially promising effects include topical capsaicin, amitriptyline, venlafaxine, multimodal pharmacological therapy, thermal radiofrequency of the stellate ganglion, and mindfulness-based cognitive therapy. For both preventive and therapeutic strategies, heterogeneity in study design, dosing regimens, and outcome frameworks, as well as the small sample size of most studies, limit the strength of evidence. Large knowledge gaps exist in the understanding of the molecular mechanisms associated with PMPS. Future research focusing on the molecular mechanisms promoting PMPS can facilitate the development of novel effective preventive and therapeutic strategies. Large-scale well-powered clinical trials on interventions aiming to prevent and treat PMPS are highly needed to inform evidence-based clinical practice. Future clinical studies should also aim to identify biomarkers that predict the efficacy of interventions in individual patients, thereby supporting personalized medicine.
2026-06-01Journal of PeriAnesthesia Nursing
Managing Anxiety in Adult Surgical Patients During Preoperative Peripheral IV Insertion: A Systematic Review of Interventions and Outcomes
Review
作者: Murphy, Erin E ; Vitale, Caitlin McManus ; Majumdar, Jennifer R ; Welch, John C ; Oballe, Christopher C ; Massaro, Christina D ; Clancy, Megan E ; Rao, Daniella N ; O'Connor, Melissa
PURPOSE:
Peripheral intravenous (PIV) insertion is a routine preoperative procedure and a common trigger of procedural anxiety in adult surgical patients. This systematic review evaluated the effectiveness of anxiety-reducing interventions-including pharmacologic, nonpharmacologic, distraction-based, cognitive-behavioral, technological, and skill-enhancement strategies-during PIV insertion in adults undergoing surgery.
DESIGN:
Systematic review conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines and registered with International Prospective Register of Systematic Reviews (CRD42025648578).
METHODS:
A comprehensive search of PubMed, CINAHL, Embase, and Web of Science was conducted through February 2025. Eligible studies included adults (≥18 years) undergoing PIV insertion in preoperative settings and evaluated interventions aimed at reducing procedural anxiety. Only randomized controlled trials and quasi-experimental studies with a control group were included. Primary outcomes were patient-reported anxiety and physiologic stress markers; secondary outcomes included pain, first-attempt success, and patient satisfaction. Screening and data extraction were performed using Covidence.
FINDINGS:
Of 5,349 records identified, 10 studies met inclusion criteria. The evidence base was small and heterogeneous, precluding meta-analysis. Lavender aromatherapy was the only intervention associated with reduced acute anxiety during PIV insertion; however, this finding was driven primarily by a single randomized controlled trial. Other interventions, including massage, hot packs, topical anesthetics, and vapocoolant sprays, more consistently improved pain and satisfaction than anxiety. Lidocaine infiltration and EMLA patches showed potential to attenuate physiologic stress responses, but anxiety outcomes were inconsistently measured across studies. No studies evaluated the effects of distraction-based, cognitive-behavioral, or technology-enabled interventions on anxiety in this population.
CONCLUSION:
Current evidence for reducing anxiety during preoperative PIV insertion is limited and low in certainty. Lavender aromatherapy appears promising, but conclusions regarding its effectiveness should be considered preliminary. The literature more consistently supports interventions for pain reduction and patient satisfaction than for anxiety reduction. Future studies should use validated anxiety measures, include adequately powered comparison groups, and evaluate both effectiveness and practical feasibility in real-world preoperative workflows.
2026-05-01Journal of Pediatric Nursing-Nursing Care of Children & Families
Effects of 4% Lidocaine and EMLA in children undergoing venous procedures on vein caliber, pain, and child collaboration: Retrospective observational study
Article
作者: Magro, Gaia ; Vecellio, Lara ; Cogo, Paola ; Dussi, Gaia ; Fabris, Stefano ; Palese, Alvisa ; Cammarata, Giorgia ; Grassetti, Luca ; Cosattini, Sofia ; Clodig, Majda ; Semeraro, Asia
BACKGROUND:
Topical anesthetics such as 4% Lidocaine and Eutectic Mixture of Local Anesthetics (EMLA) are used for venipuncture and intravenous (IV) cannulation. However, their vascular effects and outcomes remain unclear in children with difficult IV access, where vasoconstriction may compromise procedural success.
AIM:
To assess and compare (a) changes in venous area before and after application of 4% Lidocaine and EMLA, (b) skin blanching, (c) procedural pain, and (d) children's collaboration during procedures.
METHODS:
Retrospective analysis was conducted on data from 88 children (aged 1 month to 16 years) at a tertiary hospital: 44 received 4% lidocaine (November 2024) and 44 EMLA (October 2019). Clinical data were extracted from medical records, including vein area assessed by ultrasound before and after anesthetic application, as well as age-appropriate pain scales, skin blanching, and collaboration as evaluated by pediatric nurses after the procedure. Data was analyzed using t-tests, chi-square tests, and Pearson correlations.
RESULTS:
Both anesthetics reduced venous area; EMLA produced greater vasoconstriction (-26.28% vs -3.27%, p = .002) and skin blanching (72.73% vs 25%, p < .001) than 4% Lidocaine. Pain was low in both groups (p = .07). Children who received EMLA showed higher collaboration (97.73% vs 75%, p < .001).
CONCLUSION:
This study contributes to pediatric nursing science by providing objective, ultrasound-based evidence on the vascular effects of commonly used topical anesthetics and supports nurses' clinical decision-making in venous access management.
IMPLICATION FOR PRACTICE:
These findings help pediatric nurses choose optimal topical anesthetics, improving venous access and reducing procedural pain.
100 项与 复方利多卡因 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 早泄 | 欧盟 | 2013-11-15 | |
| 早泄 | 冰岛 | 2013-11-15 | |
| 早泄 | 列支敦士登 | 2013-11-15 | |
| 早泄 | 挪威 | 2013-11-15 | |
| 疼痛 | 美国 | 2006-04-27 | |
| 麻醉 | 美国 | 1992-12-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2/3期 | 22 | (2.5 g of Lidocaine 23% / Tetracaine 7% Ointment) | 積鏇廠壓淵衊窪鑰膚積(觸鹽築鹽範製積選獵憲) = 膚網鏇範夢獵遞壓製憲 衊鑰憲觸衊壓鬱鏇襯鬱 (壓膚艱窪壓壓醖艱鬱淵, 1.90) 更多 | - | 2026-02-20 | ||
(7.5 g Lidocaine 2.5%/ Prilocaine 2.5% Cream) | 積鏇廠壓淵衊窪鑰膚積(觸鹽築鹽範製積選獵憲) = 網襯衊繭網襯簾製鏇憲 衊鑰憲觸衊壓鬱鏇襯鬱 (壓膚艱窪壓壓醖艱鬱淵, 2.00) 更多 | ||||||
N/A | 72 | (Emla-cream) | 觸鏇製衊觸壓鏇艱憲構(獵餘齋襯鬱築鑰衊糧鏇) = 膚鑰齋糧顧窪製選顧憲 積鑰膚鹹廠鏇壓蓋觸蓋 (餘夢獵壓顧窪鹽餘遞衊, 網鹽願壓壓壓夢窪鑰淵 ~ 製鏇糧膚鏇廠壓遞製積) 更多 | - | 2025-10-23 | ||
Miniderm cream (Miniderm Cream) | 觸鏇製衊觸壓鏇艱憲構(獵餘齋襯鬱築鑰衊糧鏇) = 鹽廠艱範艱衊餘齋蓋衊 積鑰膚鹹廠鏇壓蓋觸蓋 (餘夢獵壓顧窪鹽餘遞衊, 窪構壓憲餘糧艱製獵夢 ~ 蓋繭選積鏇築觸鹽鹽夢) 更多 | ||||||
临床1期 | - | (male) | 顧夢獵夢糧簾繭糧襯鑰(鏇網鹽壓願製廠廠衊鑰) = 構遞鹹願膚鹽醖餘遞願 蓋鬱醖築鑰襯願窪憲獵 (簾鬱鏇鹹蓋蓋選蓋顧艱 ) 达到 | 积极 | 2023-06-28 | ||
placebo (male) | 顧夢獵夢糧簾繭糧襯鑰(鏇網鹽壓願製廠廠衊鑰) = 糧淵鑰憲製遞願窪遞願 蓋鬱醖築鑰襯願窪憲獵 (簾鬱鏇鹹蓋蓋選蓋顧艱 ) 达到 | ||||||
临床4期 | 10 | (EMLA) | 餘艱繭觸遞願憲鬱襯壓(壓遞壓遞觸獵鏇衊鹽衊) = 艱艱壓艱積構醖醖壓膚 觸遞糧夢觸夢築構鬱憲 (艱窪醖艱醖窪範網鏇遞, 艱選顧網膚願製醖顧網 ~ 積築鏇鑰艱窪構憲獵衊) 更多 | - | 2023-03-09 | ||
(Lidocaine) | 築夢淵廠範構願鬱鬱壓 = 糧選醖觸遞簾艱選壓顧 窪憲製廠繭觸襯顧淵鹽 (艱積蓋襯壓襯鏇艱觸簾, 衊夢襯襯醖窪鏇夢觸齋 ~ 簾繭觸膚淵築積窪製製) | ||||||
临床4期 | 70 | Placebo (Placebo) | 壓廠夢夢鏇遞製醖積選(糧壓範顧壓繭窪糧觸製) = 顧簾齋簾鬱衊餘繭鹽淵 鏇膚願醖壓廠製構齋夢 (憲膚積糧積獵獵選蓋襯, 4) 更多 | - | 2022-12-28 | ||
(Active Drug) | 壓廠夢夢鏇遞製醖積選(糧壓範顧壓繭窪糧觸製) = 餘壓蓋獵襯顧齋膚鹽遞 鏇膚願醖壓廠製構齋夢 (憲膚積糧積獵獵選蓋襯, 3.5) 更多 | ||||||
N/A | 354 | (EMLA Group) | 鹹廠鹹觸鑰壓餘膚鹹鹹(壓壓鹹築艱選夢醖遞願) = 窪艱艱構衊膚願願蓋繭 齋鏇鏇願廠鑰糧壓糧鹽 (鏇鹽繭淵餘襯網築願齋, 鏇窪夢簾鏇襯顧鏇夢選 ~ 構窪壓鑰鏇繭網憲觸鏇) 更多 | - | 2021-10-06 | ||
Distraction techniques (Distraction Group) | 鹹廠鹹觸鑰壓餘膚鹹鹹(壓壓鹹築艱選夢醖遞願) = 願繭鬱顧選觸遞壓鹹築 齋鏇鏇願廠鑰糧壓糧鹽 (鏇鹽繭淵餘襯網築願齋, 遞蓋衊醖窪鑰網繭鑰襯 ~ 壓製鹽膚窪膚襯蓋鹽網) 更多 | ||||||
临床4期 | 14 | Botulinum toxin type A+2.5% lidocaine/2.5% prilocaine (Topical Anesthesia) | 餘鬱願壓獵簾選醖網襯(窪願網選憲齋範製願獵) = 積淵製廠蓋膚廠簾觸獵 鏇範製範製鑰襯簾選網 (鬱鑰鹹醖餘窪蓋鑰齋鑰, 3.3) 更多 | - | 2020-06-18 | ||
Botulinum toxin type A (Petrolatum) | 餘鬱願壓獵簾選醖網襯(窪願網選憲齋範製願獵) = 艱衊糧鬱膚餘鹽獵壓網 鏇範製範製鑰襯簾選網 (鬱鑰鹹醖餘窪蓋鑰齋鑰, 3.16) 更多 | ||||||
临床4期 | 37 | (EMLA) | 鹽醖選窪餘鹽積鏇選願(齋壓衊選壓廠壓壓壓憲) = 鹽憲齋淵鏇願繭願艱製 餘鏇願襯繭餘糧願鏇獵 (築艱獵鏇鑰壓觸餘廠範, 積鏇糧繭壓鹹鏇鏇鏇積 ~ 網壓衊憲鏇簾獵積壓鹽) 更多 | - | 2020-01-18 | ||
(Lidocaine) | 鹽醖選窪餘鹽積鏇選願(齋壓衊選壓廠壓壓壓憲) = 憲鹹構憲顧醖醖窪齋艱 餘鏇願襯繭餘糧願鏇獵 (築艱獵鏇鑰壓觸餘廠範, 鹽窪鏇艱壓願鹹製鹽齋 ~ 窪鹽鏇淵壓範齋糧鬱壓) 更多 | ||||||
临床2期 | 33 | (Arm A (EMLA)) | 鑰餘選網積積齋獵醖壓(製鏇構窪獵繭糧淵構憲) = 艱窪獵鏇醖構齋淵餘遞 鹽願簾鏇襯窪廠糧顧獵 (憲淵壓壓遞積襯網膚鏇, 0.25) 更多 | - | 2019-09-06 | ||
Placebo (Arm B (Placebo)) | 鑰餘選網積積齋獵醖壓(製鏇構窪獵繭糧淵構憲) = 糧蓋襯鏇鹽簾鬱餘積窪 鹽願簾鏇襯窪廠糧顧獵 (憲淵壓壓遞積襯網膚鏇, 0.19) 更多 | ||||||
N/A | - | 66 | Placebo+EMLA Cream (EMLA Cream, Then Placebo Via J-Tip) | 鹹齋構構鏇選醖築選繭(窪網網獵鬱襯築夢廠糧) = 廠鹹窪窪窪選構鹹遞艱 選淵製醖範壓壓選積廠 (積鹹觸醖獵遞餘淵餘淵, 艱蓋鹽觸餘憲蓋網齋繭 ~ 餘構壓壓鏇選積鑰觸獵) 更多 | - | 2019-06-21 | |
Placebo+Lidocaine (Placebo Cream, Then Lidocaine Via J-Tip) | 鹹齋構構鏇選醖築選繭(窪網網獵鬱襯築夢廠糧) = 鹽簾膚醖鹽鑰艱壓積糧 選淵製醖範壓壓選積廠 (積鹹觸醖獵遞餘淵餘淵, 鏇顧餘鑰窪齋選齋艱蓋 ~ 襯餘艱齋襯糧築壓鬱廠) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用